

BCC13

Controversies in CVD

01 May
2026

 Helnan Hotel,
Port Fouad



CONFERENCE CHAIRMAN

PROGRAM DIRECTOR



PRESIDENT OF EAVA
PROF. ASHRAF REDA,
MD, FESC



VICE PRESIDENT OF EAVA
PROF. ATEF ELBAHRY

13:30 - 14:30

Registration

Open Buffet -Snacks

ASCVD RISKS CONTROVERSIES

14:30 - 15:30 Session (1)

Controversies in Hypertension

Chairpersons:

Ashraf Reda, Azza Farrag, Fathy Nada, Emad Abdelhay,
Ihab Daoud, Nada Raees, Wafik Elgamal

14:30 - 14:45 The Optimal Target Blood Pressure?

Nabil Farag

12 mins + 3 mins Discussion

**14:45 - 15:00 Treatment of Hypertension: Which
Goal for Which Patient?**

Ahmed Elhawary

12 mins + 3 mins Discussion

**15:00 - 15:15 Should Blood Pressure Goal Be
Individualized in Hypertensive
Patients?**

Mohammed Elmerry

12 mins + 3 mins Discussion

15:15 - 15:30 Company Symposium (1):



**Chartoreg: Telmisartan Power Of
Control And Protection**

Atef Elbahry

15 mins + 3 mins Discussion

15:30 - 16:30 **Session (2)**
Controversies in Dyslipidemia

Chairpersons:

Ahmed Elhawary, Ismail Aly, Magdy Matter,
Mohamed Abdelghany, Mohammed Elmerry, Nabil Farag.

15:30 - 15:45 **Treatment Thresholds, In Patients
with Chronic Kidney Disease**
Emad Abdelhay
12 mins + 3 mins Discussion

15:45 - 16:00 **The Use of Risk Calculators, and
Variations Between Different
International Guidelines**
Azza Farrag
12 mins + 3 mins Discussion

16:00 - 16:15 **What is the Best Marker for
Dyslipidemia? LDL-C or Non-HDL-C**
Ashraf Reda
12 mins + 3 mins Discussion

16:15 - 16:30 **Company Symposium (2):
LEQVIO ; Don't Miss The Window To
Prevent What Is Next**



Emad Abd El Hay
12 mins + 3 mins Discussion

16:30 - 17:15

Session (3)

Controversies in Atherothrombosis

Chairpersons:

Ahmed Shawky, Hany Ragy, Mohamed Abdelghany,
Reneh Ramzy, Mohamed Khedr, Sameh Emil, Seif Kamal,
Yasser Baghdady.

16:30 - 16:45

**Genotype-Guided Antiplatelet
Therapy**

Atef Elbahry

12 mins + 3 mins Discussion

16:45 - 17:00

**Controversies Exist Regarding
the Optimal Use of Antiplatelet and
Anticoagulant Agents to Prevent
Ischemic Events while Minimizing
the Risk of Bleeding**

Elsayed Farag

12 mins + 3 mins Discussion

17:00 - 17:15

**Company Symposium (3):
Comprehensive Cardiovascular
Risk Management**



Yasser Huzayen

12 mins + 3 mins Discussion

17:15 - 18:15

**Session (4)
Controversies in Heart Failure**

Chairpersons:

Ahmed Elkersh, Atef Elbahry, Duaa Dergham,
Elsayed Farag, Inass Shaltout

**17:15 - 17:30 The best Diagnostic Criteria and
Management For Heart Failure With
a Preserved Ejection Fraction (HFpEF)**

Yasser Baghdady

12 mins + 3 mins Discussion

**17:30 - 17:45 Therapeutic Controversies in Heart
Failure**

Sameh Emil

12 mins + 3 mins Discussion

17:45 - 18:00 Barriers for the 4 Pillars of HFREF

Ahmed Shawky

12 mins + 3 mins Discussion

**18:00 - 18:15 Company Symposium (4):
Finoxlab: A TURNING POINT IN CMR
PROTECTION**



Atef Elbahry

12 mins + 3 mins Discussion

18:15 - 19:00

Session (5)

Controversies in Obesity

Chairpersons:

Ahmed Elkersh, Elsayed Elmasry, Gamela Nasr,
Hazem Khamis, Heba Attia, Nireen Okasha,
Iman Elsherif

18:15 - 18:30

While Genetics Play a Role, the Rapid Increase in Obesity Rates Suggests that Other Factors are Dominant

Gehan Fouad

12 mins + 3 mins Discussion

18:30 - 18:45

The Metabolic Reset: Unlocking the Full Potential of Anti-Obesity Medications, and What's after discontinuation?

Inass Shaltout

12 mins + 3 mins Discussion

18:45 - 19:00

What is Clinical and Preclinical Obesity?

Yasser Huzayen

12 mins + 3 mins Discussion

19:00 - 19:45 **Session (6)**
Controversies in CHD

Chairpersons:

Hany Ragy, Mohamed Abdelghany, Yasser Huzayen

19:00- 19:15 **Neither PTCA or Medical Therapy is Universally Clear**

Hazem Khamis

12 mins + 3 mins Discussion

19:15 - 19:30 **ANOCA /INOCA /MINOCA Clinical Phenotypes**

Nireen Okasha

12 mins + 3 mins Discussion

19:30 - 19:45 **Controversy of CHD in Children**
Heba Attia

12 mins + 3 mins Discussion



19:45 Dinner